选择性色素再吸收抑制剂相关的内出血:药物特异性风险模式和患者水平的修饰剂
1Department of Internal Medicine, Division of Pulmonary, Allergy and Sleep Medicine, HELIOS Clinic Wuppertal, Witten/Herdecke University, Heusnerstr. 40, 42283 Wuppertal, Germany.
Neurology international
|July 25, 2025
概括
选择性血红素再吸收抑制剂 (SSRI) 可能会增加内出血 (ICH) 风险,特别是老年患者或服用抗凝剂的患者的塞特拉林和素. 西塔洛普拉姆显示有保护作用.
科学领域:
- 药物监督 药物监督 药物监督
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
背景情况:
- 选择性血清素再吸收抑制剂 (SSRI) 是广泛处方的抗抑郁药.
- 新出现的证据表明,SSRI使用与内出血 (ICH) 之间存在潜在联系.
- 在老年人和同时使用抗凝血剂的人群中,这种风险可能会增加.
研究的目的:
- 调查特定的SSRI和ICH事件之间的关联.
- 确定改变这种风险的患者人口统计和并发药物.
- 为了比较不同SSRI之间的ICH报告模式.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库的回顾性药监分析.
- 包括与六种常见的SSRI相关的ICH事件 (塞特拉林,西丁,帕洛克塞丁,埃斯基塔洛普拉姆,西塔洛普拉姆,弗卢瓦克萨明).
- 使用报告几率比率 (ROR) 评估风险信号的不成比例分析.
主要成果:
- 在ICH病例中,塞特拉林,帕洛克塞丁和弗洛克塞丁是最常见的.
- 塞特拉林显示大脑出血的显著信号 (ROR=4.97),特别是在60岁以上的患者 (ROR=7.92) 和服用抗凝剂 (ROR=9.56) 的患者中.
- 西与下关节出血有关 (ROR=4.51);西塔洛普拉姆与脑出血有相反的关联.
结论:
- 在不同的SSRI中,ICH报告模式在不同SSRI中有很大差异.
- 患者的年龄,性别和同时使用抗凝剂是影响SSRI相关的ICH风险的关键因素.
- 个性化的SSRI处方是必不可少的,在高风险人群中建议对塞特拉林和弗洛克塞丁采取谨慎措施.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
299
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
299
Antidepressant Drugs: MAOIs and Other Agents
358
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
358
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
580
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
580
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
405
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
405
Hazard Ratio
251
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
251


